Navigation Links
WuXi PharmaTech Honored on the Deloitte Technology Fast 500 Asia Pacific 2008 List for the Fifth Consecutive Year
Date:2/8/2009

SHANGHAI, China, Feb. 8 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, is proud to announce that it was selected for the Deloitte Technology Fast 500 Asia Pacific 2008 list for the fifth consecutive year. The Deloitte program recognizes technology companies in the Asia Pacific region that have achieved the fastest rates of annual revenue growth during the past three years. WuXi PharmaTech is one of only 13 companies to be so recognized for five years in a row and the only such company in China.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"Achieving our place in this ranking of Asia Pacific's elite growth companies is recognition of our successful business model," commented Mr. Benson Tsang, Chief Financial Officer of WuXi PharmaTech. "Our business is built around an intense focus on meeting the needs of our biopharmaceutical and medical device partners to improve R&D productivity. We are continuing to make steady progress in expanding our service portfolio to provide a global, fully integrated, high-quality R&D service platform. Our ongoing work to begin GLP toxicology operations in Suzhou, in what will be the largest such facility in China, and to integrate WuXi operations with those of U.S.-based AppTec Laboratory Services, Inc., represent important milestones in that effort."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5515
     Email: ir@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
2. WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
3. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
4. WuXi PharmaTech Announces Second Quarter 2008 Results
5. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
6. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
7. WuXi PharmaTech 2007 Annual Report Available Online
8. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
9. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
10. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
11. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
Breaking Medicine Technology: